People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Caffeine Affects Brain Dopamine Function in Patients With Parkinson's Disease May 28, 2024 — Regular high caffeine consumption affects dopamine function in patients with Parkinson's disease ...

The findings revealed that an overwhelming 84% of patients with Parkinson’s disease report struggling with sleep issues—significantly higher than the general population of the same age group. The ...

A man fitted with a pioneering, computer-controlled brain implant to tackle his Parkinson's disease says it ... on the quality of life of patients with the disease. He began getting symptoms ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

CyberKnife radiosurgery is a 15-minute outpatient procedure that requires no anesthesia or hospital admission, offering a non-invasive alternative to traditional surgeries for treating Parkinson’s ...